Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
|Articles|May 23, 2022
The Mainstream Patient: May 23
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about the top 10 best acne-fighting ingredients and medications in 2022, Bill Nye talks not using oil on the scalp, and more.
Advertisement
In this week’s edition, Self interviews Samantha Tan, Race Car Driver, on eczema and InStyle claims to list the only dermatologist-approved at home anti-aging device. Cosmopolitan lists the best acne treatments and Glamour talks hair oil. Elle explains supplements and Allure talks topical steroid withdrawl.
Race Car Driver Samantha Tan on Eczema, Mental Health, and Why Asian Representation Matters
This Is the One Anti-Aging Device a Dermatologist Recommends Using at Home
10 Best Acne-Fighting Ingredients, Medications, and Treatments of 2022
Bill Nye Is Begging You to Not Use Oil on Your Scalp
The Supplements To Consider Taking At Every Life Stage
What It's Like to Live With Topical Steroid Withdrawal
Advertisement
Related to this article
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5